

## UPCOMING RELEASE OF SECURITIES FROM ESCROW

---

In accordance with ASX Listing Rule 3.10A, Bio-Gene Technology Limited [ASX:BGT] advises that the following securities will be released from escrow on 29 November 2019:

- 12,523,305 ordinary shares;
- 2,000,000 Broker Options, exercisable at 20 cents and expiring on 24 November 2020

An Appendix 3B will be released in respect of the shares following the release from escrow.

- ENDS -

### For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger

Chief Executive Officer

P: 03 9068 1062

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Roger McPherson

CFO & Company Secretary

P: 03 9068 1062

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Media/investor relations:

Davina Gunn

Henslow

T: 0400 896 809

E: [dgunn@henslow.com](mailto:dgunn@henslow.com)

### About Bio-Gene Technology Ltd

Bio-Gene is an Australian AgTech company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, consumer applications and animal health. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.